Shorter treatment for drug-sensitive lung tuberculosis using higher rifampicin
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether you can take a shorter course of standard treatment for drug-sensitive pulmonary (lung) tuberculosis by using a higher dose of rifampicin. It may help some people finish treatment sooner, while doctors track how well the infection clears.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung TB test (Xpert MTB/RIF) must be positive
- You must start the trial within 7 days of beginning your current TB medicines
- Your Xpert MTB/RIF result must not show rifampicin resistance
- You must not be known to be resistant to isoniazid, rifampicin, or pyrazinamide
- You must not have HIV
- You must not have serious liver disease or uncontrolled diabetes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for TB that is resistant to the drug rifampicin but still sensitive to isoniazid. It may help people finish treatment sooner and with fewer side effects.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This study tests whether adding sitafloxacin to certain short tuberculosis (TB) treatment plans can cure TB faster while staying safe. You may be eligible if you have drug-susceptible lung TB and your TB bacteria are sensitive to several specific TB medicines.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.